The Alzheimer's Drug Debate

Chamath, Jason, and David discuss the ethical and financial implications of approving an Alzheimer's drug with limited evidence of clinical benefits. They delve into the disproportionate impact of the disease on minorities and women, the history of failed Alzheimer's drugs, and the potential risks of false hope and setting a precedent for drug approvals.